Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Authors: Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang‐Xuan, Alba A. Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel, Christian Hartmann, Gail Ryan, David Capper, Johan M. Kros, Sebastian Kurscheid, Wolfgang Wick, Roelien H. Enting, Michele Reni, Brian Thiessen, F. Dhermain, Jacoline E. C. Bromberg, L. Feuvret, Jaap C. Reijneveld, Olivier Chinot, Johanna M. M. Gijtenbeek, John P. Rossiter, Nicolas Dif, Carmen Balañá, Jose Bravo-Marques, Paul M. Clément, Christine Marosi, Tzahala Tzuk-Shina, Robert Nordal, Jeremy Rees, Denis Lacombe, Warren Mason, Roger Stupp - The Lancet 2016 cited by 498